The Zurich based Pregnolia developed an innovative system to accurately assess the stiffness of the cervical tissue of pregnant and non-pregnant women. Cervical stiffness and length are used to assess changes in the cervix during pregnancy. Pregnolia's test can easily be integrated into routine pregnancy checkups by the gynecologist and takes less than a minute to administer.
The startup has now closed its seed round with investiere as the largest investor in the round, contributing CHF 1.7 million. The rest of the funds were raised by Zürcher Kantonalbank and the investment department of CADFEM, a software provider active in the medical field.
“We are thrilled that we can write the next chapter of Pregnolia’s journey,” states Sabrina Badir, founder and CEO of Pregnolia. “With investiere we have a great partner at our side. investiere played a key role in securing the success of this financing round and we are proud to be part of the its family.”
In addition to the round, Pregnolia welcomed two board members from Investiere’s community, Bruno Reihl and Marc Kohler. Both have decades of valuable experience in the healthcare and medtech sector. Bruno Reihl is a serial entrepreneur and the former CEO of the medtech company Raumedic. He has an extensive network and a deep understanding of the various challenges that a young medtech company faces. Marc Kohler has been the CEO of the Spital Thurgau AG for the last 14 years. He is an active business angel with more than 20 years of experience and has sat on the board of numerous medtech and life science companies.
The ETH spin-off has already produced a series of 1'000 devices together with renowned medical suppliers and has been conducting the relevant clinical testing. Pregnolia was able to fund its first phase of development without raising funds from investors, creating a fully functioning prototype with funds obtained through grants and prize money from numerous awards, including the W.A. de Vigier Award in 2016.